Active Ingredient History

  • Now
Satavaptan is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009.   Wikipedia

  • SMILES: CCOc1ccc2N(C(=O)[C@@]3(CC[C@H](CCN4CCOCC4)CC3)c2c1)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C
  • Mol. Mass: 627.8
  • ALogP: 4.51
  • ChEMBL Molecule:
More Chemistry
1-(4-(n-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro-(4-(2-morpholinoethoxy)cyclohexane)indol-2-one fumarate | 1-(4-(n-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro(4-(2-morpholinoethoxy)cyclohexane)indoline-2-one, phosphate monohydrate cis-isomer | satavaptan | sr-121463 | sr 121463a | sr-121463a | sr121463b | sr-121463b | sr-121463f


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue